Cargando…

A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part

Detalles Bibliográficos
Autores principales:	Koch, Sven D, Hong, Henoch, Feyerabend, Susan, Retz, Margitta, Kuebler, Hubert, Heidenreich, Axel, van Erps, Thomas, Schroeder, Andreas, Scheel, Birgit, Reus, Valérie, Kallen, Karl-Josef, Fotin-Mleczek, Mariola, Gnad-Vogt, Ulrike, Stenzl, Arnulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288759/ http://dx.doi.org/10.1186/2051-1426-2-S3-P85

Ejemplares similares

A novel, disruptive vaccination technology: Self-adjuvanted RNActive(®) vaccines
por: Kallen, Karl-Josef, et al.
Publicado: (2013)

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy
por: Hong, Henoch S., et al.
Publicado: (2016)

Self-adjuvanted RNActive(® )vaccines provide a promising platform for combination therapies with checkpoint inhibitors
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
por: Sebastian, Martin, et al.
Publicado: (2014)

Self-adjuvanted RNActive(® )vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses
por: Kallen, Karl-Josef, et al.
Publicado: (2013)

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
por: Kübler, Hubert, et al.
Publicado: (2015)

RNAdjuvant(®), a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile
por: Heidenreich, Regina, et al.
Publicado: (2015)

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors
por: Fotin-Mleczek, Mariola, et al.
Publicado: (2014)

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
por: Papachristofilou, Alexandros, et al.
Publicado: (2019)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
por: Rauch, Susanne, et al.
Publicado: (2021)

LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2022)

Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2023)

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals
por: Thess, Andreas, et al.
Publicado: (2015)

Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial
por: Haas, Naomi B, et al.
Publicado: (2015)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
por: Lutz, Johannes, et al.
Publicado: (2017)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial
por: Ernst, T, et al.
Publicado: (2007)

Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial
por: Hofheinz, R-D, et al.
Publicado: (2004)

mRNA mediates passive vaccination against infectious agents, toxins, and tumors
por: Thran, Moritz, et al.
Publicado: (2017)

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response
por: Edwards, Darin K., et al.
Publicado: (2017)

Experimental designs for phase I and phase I/II dose-finding studies
por: O'quigley, J, et al.
Publicado: (2006)

Phase I and Phase II CMS upgrade
por: Heister, A
Publicado: (2014)

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
por: McNeel, Douglas G, et al.
Publicado: (2022)

Phase I trial of elactocin.
por: Newlands, E. S., et al.
Publicado: (1996)

T2K Phase-I
por: Ishida, T
Publicado: (2005)

ATLAS Trigger in Phase-I
por: ATLAS Collaboration, et al.
Publicado: (2016)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
por: Taghizadeh, H., et al.
Publicado: (2019)

Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
por: de Angelis, Cristina, et al.
Publicado: (2021)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
por: Rosar, Florian, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer
por: Hofheinz, R-D, et al.
Publicado: (2004)

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
por: Brosch-Lenz, Julia, et al.
Publicado: (2021)

HIE-ISOLDE Phase I celebration
por: Ordan, Julien
Publicado: (2016)

Phase I Cancer Clinical Trials
por: Ledermann, J A
Publicado: (2007)

Magnets for the phase I LHC upgrade
por: Fessia, P
Publicado: (2009)

The CMS Phase I pixel detector
por: Gray, Julia Ann
Publicado: (2013)

Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies
por: Emanuel, Ezekiel J, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kgoibrfac6ikp6ss504tuhu6uq